RTW Investments, LP and Roderick Wong, M.D. filed an amended Schedule 13G/A reporting shared beneficial ownership of 5,940,866 shares of Stoke Therapeutics common stock, representing 9.99% of the class. The filing states this percent assumes exercise of 317,341 warrants and uses February 28, 2026 as the as of date for 59,150,790 shares outstanding. The Reporting Persons disclose shared voting and dispositive power over the reported shares and note that RTW Funds, including RTW Master Fund Ltd., have the right to receive dividends or sale proceeds.
Positive
None.
Negative
None.
Insights
RTW reports a near-10% shared stake via funds and the CIO.
RTW Investments and Dr. Roderick Wong report shared ownership of 5,940,866 shares, equal to 9.99%, calculated on February 28, 2026 with assumed exercise of 317,341 warrants. The filing attributes voting and dispositive power as shared rather than sole.
Cash‑flow treatment and any planned disposition are not stated in the excerpt; future filings would disclose transactions if holders trade. The immediate investor takeaway is an identified large, shared position that may influence governance or liquidity depending on later actions.
Shared power and fund-level ownership are emphasized; an RTW fund holds >5%.
The filing specifies that the RTW Funds have the right to receive dividends or proceeds and that RTW Master Fund Ltd. holds more than 5% of the class. Voting and dispositive powers are reported as shared for both Reporting Persons.
Because the position is reported on a Schedule 13G/A, the disclosure signals passive institutional ownership reporting rather than an active Section 13(d) acquisition. Subsequent Form 13D/4 filings would be required if the intent or control status changes.
Key Figures
Shares beneficially owned:5,940,866 sharesPercent of class:9.99%Warrants assumed exercisable:317,341 warrants+1 more
4 metrics
Shares beneficially owned5,940,866 sharesshared ownership reported by RTW Investments and Dr. Wong
Percent of class9.99%percentage assuming exercise of warrants, calculated on <date>February 28, 2026</date>
Warrants assumed exercisable317,341 warrantsmaximum exercisable given current outstanding shares per filing
Shares outstanding59,150,790 sharesreported as of <date>February 28, 2026</date> from company 10-K
"assume the exercise of warrants held by the Reporting Persons to purchase 317,341 Shares"
Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.
Beneficially ownedregulatory
"Amount beneficially owned: The information required by Item 4(a) is set forth"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
Shared dispositive powerregulatory
"Shared dispositive power 5,940,866.00"
Schedule 13G/Aregulatory
"filed an amended Schedule 13G/A reporting shared beneficial ownership"
A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.
What stake does RTW Investments report in Stoke Therapeutics (STOK)?
RTW Investments and Roderick Wong report shared beneficial ownership of 5,940,866 shares, equal to 9.99% of the class. This percentage assumes exercise of 317,341 warrants and is calculated on February 28, 2026 using 59,150,790 shares outstanding.
Does the filing show who controls voting or sale decisions for the shares?
The filing reports shared voting and shared dispositive power for both RTW Investments and Dr. Wong. It states the RTW Funds have the right to receive dividends or sale proceeds, and RTW Master Fund Ltd. holds over 5%.
Are warrants included in RTW's reported ownership for STOK?
Yes. The reported 9.99% calculation assumes the exercise of 317,341 warrants held by the Reporting Persons, limited by a 9.99% ownership cap under the warrant terms as described in the filing.
Is this Schedule 13G/A indicative of an activist intent for STOK?
No. The filing is a Schedule 13G/A amendment reporting passive ownership at the fund level. It does not state activist intentions; any change to active intent or control would require a different filing such as a Form 13D.
What is the effective outstanding share count used in the filing for STOK?
The filing uses an outstanding share count of 59,150,790 shares as of February 28, 2026, sourced from the company’s Annual Report on Form 10-K referenced in the amendment.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 7)
Stoke Therapeutics, Inc.
(Name of Issuer)
Common Stock, par value $0.0001 per share
(Title of Class of Securities)
86150R107
(CUSIP Number)
03/31/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
86150R107
1
Names of Reporting Persons
RTW Investments, LP
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
5,940,866.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
5,940,866.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
5,940,866.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.9 %
12
Type of Reporting Person (See Instructions)
IA, PN
SCHEDULE 13G
CUSIP Number(s):
86150R107
1
Names of Reporting Persons
Roderick Wong
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
5,940,866.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
5,940,866.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
5,940,866.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.9 %
12
Type of Reporting Person (See Instructions)
HC, IN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Stoke Therapeutics, Inc.
(b)
Address of issuer's principal executive offices:
45 Wiggins Ave, Bedford, MA, 01730.
Item 2.
(a)
Name of person filing:
This statement is filed by:
(i) RTW Investments, LP ("RTW Investments"), a Delaware limited partnership and the investment adviser to certain funds (the "RTW Funds"), with respect to shares of Common Stock, par value $0.0001 per share (the "Shares") of Stoke Therapeutics, Inc. (the "Company") directly held by the RTW Funds; and
(ii) Roderick Wong, M.D. ("Dr. Wong"), the Managing Partner and Chief Investment Officer of RTW Investments, with respect to the Shares directly held by the RTW Funds.
The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons."
The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, as amended, the beneficial owner of the Shares reported herein.
(b)
Address or principal business office or, if none, residence:
The address of the business office of each of the Reporting Persons is 40 10th Avenue, Floor 7, New York, New York 10014.
(c)
Citizenship:
RTW Investments is a Delaware limited partnership. Dr. Wong is a citizen of the United States.
(d)
Title of class of securities:
Common Stock, par value $0.0001 per share
(e)
CUSIP No.:
86150R107
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
The information required by Item 4(a) is set forth in Rows 5 - 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The amounts reported herein assume the exercise of warrants held by the Reporting Persons to purchase 317,341 Shares (the "Warrants"), the maximum amount that may be exercised given the current number of outstanding shares and the shares held by the Reporting Persons. Pursuant to the terms of the Warrants, the Reporting Persons cannot exercise any of the Warrants to the extent the Reporting Persons would beneficially own, after any such exercise, more than 9.99% of the outstanding Shares. The percentages set forth in Row 11 of the cover pages are calculated based upon 59,150,790 Shares outstanding as of February 28, 2026 as reported in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC") on March 16, 2026, and assume the exercise of Warrants held by the Reporting Persons to purchase 317,341 Shares.
(b)
Percent of class:
RTW Investments: 9.99%
Dr. Wong: 9.99%
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
RTW Investments: 0
Dr. Wong: 0
(ii) Shared power to vote or to direct the vote:
RTW Investments: 5,940,866 Shares
Dr. Wong: 5,940,866 Shares
(iii) Sole power to dispose or to direct the disposition of:
RTW Investments: 0
Dr. Wong: 0
(iv) Shared power to dispose or to direct the disposition of:
RTW Investments: 5,940,866 Shares
Dr. Wong: 5,940,866 Shares
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
See Item 2. The RTW Funds have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Shares reported herein. RTW Master Fund Ltd., an RTW Fund, has the right to receive or the power to direct the receipt of dividends or the proceeds from the sale of more than 5% of the Shares.
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
RTW Investments, LP
Signature:
/s/ Roderick Wong, M.D.
Name/Title:
Roderick Wong, M.D., Managing Partner
Date:
05/15/2026
Roderick Wong
Signature:
s/ Roderick Wong, M.D.
Name/Title:
Roderick Wong, M.D.
Date:
05/15/2026
Exhibit Information
Exhibit 99.1 Joint Filing Agreement (incorporated by reference to Exhibit 1 to the Reporting Persons' Schedule 13G filed with the SEC on February 12, 2021).
